Copyright
©The Author(s) 2021.
World J Hepatol. Dec 27, 2021; 13(12): 2024-2038
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2024
Published online Dec 27, 2021. doi: 10.4254/wjh.v13.i12.2024
PFIC 4 | PFIC 5 | PFIC 6 | |
Gene mutation | TJP2/Zona occludens-2 located in 9q21.11 | NR1H4/FXR-located in 12q23.1 | MYO5B located in 18q21.1 |
Clinical features | |||
Clinical features | Cholestatic jaundice with pruritus | Rapidly progressive neonatal-onset cholestasis with uncorrectable coagulopathy | Cholestasis with pruritus, with/without transient, recurrent or progressive diarrhea (association with MVID) |
Extrahepatic features | Neurological and respiratory symptoms | - | - |
ICP | Yes | Yes (uncommon) | No |
Laboratory parameters | |||
AST/ALT | Elevated | Moderate elevation | Mild to moderate elevation |
GGT | Normal or mild elevation | Normal | Normal |
Coagulopathy | Late-onset | Early-onset | Late-onset |
Alpha fetoprotein | Normal, elevated in cases with HCC | Elevated | Normal |
S. Bile acids | Elevated | Elevated | Elevated |
Histopathology | |||
Canalicular cholestasis | Yes | Yes | Yes |
Portal/lobular fibrosis | Yes | Yes | Yes |
Giant-cell transformation | Yes | Diffuse | Sparse |
Ductular reaction | No | Yes | Yes |
Hepatocyte necrosis | Yes | - | - |
Cirrhosis | Yes | Yes | Less common |
Immunohistochemistry | |||
BSEP | Present | Absent BSEP staining on bile canaliculus | Abnormally thick, irregular and granular positivity that overflows into subcanalicular area |
MDR3 | Present | Present | Thickened canalicular staining granular and patchy pattern overflows into subcanalicular area |
TJP2 | Absent expression in canalicular membrane | Present | Present |
Claudin1 | Absent or reduced staining on bile canaliculi | Present | Present |
FXR | Normal | Absent staining on bile canaliculus | Normal |
MYO5B/RAB11 | Normal | Normal | Intense, granular staining pattern in hepatocyte cytoplasm, and weak/loss of canalicular expression |
Progression | Rapid | Very rapid | Slow |
Complications | Hepatocellular carcinoma | Post-transplant graft steatosis similar to PFIC1 | Worsening of cholestasis post intestinal transplant |
Treatment | |||
Medical management | UDCA, Rifampicin | Minimal role | UDCA, rifampin, cholestyramine |
Biliary diversion | PEBD some role | Not tried | Cholestasis subsides after BD in MVID patients with cholestasis |
Liver transplant | Yes | Yes | Yes. Combined liver intestinal transplant in children with MVID and ongoing cholestasis |
- Citation: Vinayagamoorthy V, Srivastava A, Sarma MS. Newer variants of progressive familial intrahepatic cholestasis. World J Hepatol 2021; 13(12): 2024-2038
- URL: https://www.wjgnet.com/1948-5182/full/v13/i12/2024.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i12.2024